Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Cassava Sciences Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Rex Fang & Innovation Equity Premium Income ETF is far larger — about 18.9× Cassava Sciences Inc's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Cassava Sciences Inc for 37 Days on average.
| FEPI | FLNA | |
|---|---|---|
Market Cap | $746.48M | $39.40M |
Volume | 334,337 | 759,018 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $4.64 |
52-Week Low | $37.98 | $0.68 |
Typical Hold Time | 56 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.18, down 0.94% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show support at $43 and resistance at $44, with RSI suggesting potential overbought conditions. Recent news highlights FEPI's 25% yield but notes underperformance versus peers in total returns.
The outlook remains income-focused with high yield appeal, though capped upside and concentrated tech exposure present risks. Elevated volatility in AI sectors could impact distributions, while competitive covered call ETFs offer alternatives. Investors should weigh income stability against total return potential and sector concentration risks in the current market environment.
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
